Company profile: Tilt Biotherapeutics
1.1 - Company Overview
Company description
- Provider of oncolytic viral cancer immunotherapies that enable tumor T-cell therapy by modifying the tumor microenvironment. Pipeline includes TILT-123 (cytokine-armed oncolytic adenovirus, in Phase 1), TILT-234 (Ad3 armed with human CD40L, ready for CMC/regulatory), TILT-321/322 (bispecific antibody-coding adenoviruses, discovery), and TILT-452 (preclinical), with clinical trial collaborations on TILT-123 with Merck KGaA and MSD.
Products and services
- Oncolytic Viral Therapies: Patented platform that architects oncolytic virus-based products to modify the tumor microenvironment, enhance immune responses, and enable tumor T-cell therapy in cancer immunotherapy contexts
- TILT-123: Clinical-stage cytokine-armed oncolytic adenovirus engineered for cancer immunotherapy, currently in Phase 1 trials for various cancers including ovarian and lung cancer
- Clinical Trials Collaboration: Combination-therapy collaborations with Merck KGaA and MSD investigating TILT-123 together with other immunotherapies in clinical studies to explore combined cancer immunotherapy applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tilt Biotherapeutics
Spectrum Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, targeted biopharmaceuticals focused on acquiring, developing, and commercializing therapies in oncology and hematology. Products include ROLVEDON (reduces severe neutropenia in non-myeloid malignancies on myelosuppressive drugs), SYMPAZAN (Lennox-Gastaut seizures), SPRIX (short-term pain), Otrexup (RA, psoriasis), Cambia (acute migraine), and INDOCIN (RA, AS, OA).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectrum Pharmaceuticals company profile →
Artbio
HQ: United States
Website
- Description: Provider of clinical-stage alpha radioligand medicines and enabling technologies, including AB001, a 212Pb-based radiopharmaceutical candidate for prostate cancer in Phase I/II trials; AlphaDirect technology for isolating Pb-212 to enable distributed manufacturing; and a distributed end-to-end manufacturing network to deliver therapeutic candidates rapidly and flexibly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artbio company profile →
ProNova Solutions
HQ: United States
Website
- Description: Provider of compact proton therapy systems and project development services for cancer treatment. Offers the ProNova SC360 with pencil beam scanning and cone-beam CT imaging, leveraging superconducting magnet technology in the cyclotron and treatment gantry, and supports design, construction, equipment installation, commissioning, and clinical start-up of proton therapy centers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProNova Solutions company profile →
Eleison Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage oncology drug candidates for orphan cancers through acquisition, development, and commercialization, including Glufosfamide (glucose-linked ifosforamide mustard targeting cancer cells to reduce normal-cell toxicity), Inhaled Lipid-Complexed Cisplatin for lung diseases (prolonged effect, enhanced uptake, reduced systemic toxicity), and Dibromodulcitol requiring further safety-equivalence studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleison Pharmaceuticals company profile →
Anaveon
HQ: Switzerland
Website
- Description: Provider of IL-2-based immunotherapies developing selective IL-2 complexes that promote effector T cell functions as immune adjuvants for cancer, with candidates including ANV419, an IL-2 agonist that favors effector over regulatory T cells and shows clinical efficacy, and ANV600, a bispecific targeting IL-2 to tumor-specific cells, with Phase 1/2 planned for Q2/2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaveon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tilt Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tilt Biotherapeutics
2.2 - Growth funds investing in similar companies to Tilt Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tilt Biotherapeutics
4.2 - Public trading comparable groups for Tilt Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →